Based on Your Reading:
Get a Mesothelioma Treatment Guide
Find a Top Mesothelioma Doctor
Access Help Paying for Treatment
Bevacizumab
Table Of Contents
As one of the world’s best-selling cancer drugs, bevacizumab is quickly becoming a promising option for mesothelioma patients. Also known as the brand name Avastin, bevacizumab inhibits the formation of new blood vessels in tumors, effectively slowing the growth of cancer cells.
Written by Karen Selby, RN | Medically Reviewed By Dr. Jeffrey Velotta | Edited By Walter Pacheco | Last Update: June 27, 2024
"Most helpful, steered us in the right direction for treatment. Great source of information and support, the Center followed through on every one of our requests...." see more
Elaine C.
Mesothelioma Patient
"Because of their guidance, I was able to navigate getting my mother into MD Anderson when her case got put aside by mistake in all the COVID-19 craziness. Vanes...." see more
Deanna B.
Daughter of a Mesothelioma Patient
"Hearing the news about my mother's diagnosis was heartbreaking. I felt lost, I didn't know how I could help or where to seek the best medical care. I started re...." see more
Danielle W.
Daughter of a Mesothelioma Patient
"My son Carlos was diagnosed with this terrible and unknown disease a few months ago. Thank God we found The Mesothelioma Center along the way, and Vanessa Blanc...." see more
Martha M.
Mother of a Mesothelioma Patient
"Extremely communicative and helped my dad get an appointment with one of the top centers in Philadelphia. I'm so grateful for this center. They assisted with in...." see more
Sunni H.
Loved One of a Mesothelioma Patient
"Danielle DiPietro was an invaluable resource for me. Her suggestions and recommendations guided us towards stellar practitioners in our area. Without her advoca...." see more
Deborah C.
Spouse of a Mesothelioma Patient
"I was very grateful and appreciative of Dr. Smart from The Mesothelioma Center. She was very helpful to my husband and me. She educated and walked us through th...." see more
Kimberlin C.
Spouse of a Mesothelioma Patient
"In January of 2016, my husband was diagnosed with peritoneal mesothelioma. Our first reaction was: what is this and what can we do? He was diagnosed by an oncol...." see more
Gloria R.
Spouse of a Mesothelioma Patient
Written by Karen Selby, RN | Medically Reviewed By Dr. Jeffrey Velotta | Edited By Walter Pacheco | Last Update: June 27, 2024
What Is Bevacizumab?
Bevacizumab is cancer fighting drug that is sometimes classified as a chemotherapy drug. It is an antiangiogenic agent, meaning that it stops blood vessel formation. This stops the supply of oxygen and nutrients to tumors to slow their growth and spread.
Doctors may inject it or give it through an intravenous drip, a process that can take a few hours. Patients generally need the drug once every three weeks. In 2021, researchers studied how well bevacizumab worked with atezolizumab for mesothelioma patients. After one year, 61% of these patients had no further signs of disease and 85% were still alive.
Researchers tested a drug called bevacizumab (Avastin) on some people with mesothelioma. They combined it with cisplatin and pemetrexed (Alimta). In a study done in France in 2016, the people taking all three drugs lived an average of 18.8 months. This compared to 16.1 months for those who only took chemotherapy alone.
In early clinical trials, bevacizumab (Avastin) helped some mesothelioma patients live longer when combined with chemotherapy drugs cisplatin and pemetrexed (Alimta). In a 2016 phase III clinical trial in France, patients taking a combination of the three drugs survived an average of 18.8 months, compared to 16.1 months for patients only receiving cisplatin and pemetrexed.
Bevacizumab has rare but serious side effects. The phase III clinical trial showed that most of these were not too difficult to deal with.
How Does Bevacizumab Work?
Bevacizumab works differently than chemotherapy. It stops tumors from getting oxygen and nutrients. It inhibits angiogenesis, which is the growth of blood vessels within the tumor.
When angiogenesis happens, it helps the mesothelioma cells in the body to grow and spread. But if there is no angiogenesis, the cancer cells don’t get enough of what they need to survive and eventually die off.
Bevacizumab can stop mesothelioma from spreading and kills cancer cells that are already present.
Bevacizumab Information
| Name | Avastin |
| Alternate Names | Bevacizumab |
| Manufacturer | Roche/Genetech |
| Dosage | 15 mg/kg every three weeks |
| Administration Route | Intravenous |
| Active Ingredient | Bevacizumab |
| Drug Class | Anti-angiogenic agent |
| Medical Code | J9035, C9257 |
| Related Drug | Bevacizumab-awwb (Mvasi) |
| Interacting Drug | Quadramet, deferiphrone, pantiumumab, sunitinib, thalidomide |
| Medical Studies | Cisplatin, Pemetrexed and Bevacizumab for Untreated Malignant Mesothelioma |
| FDA Warning | Gastrointestinal perforation or fistula, arterial thromboembolic events, hypertension, proteinuria, ovarian failure, infusion reactions, posterior reversible encephalopathy syndrome |
It is used in combination with other chemotherapy drugs such as a cisplatin-based chemotherapy regimen. Some clinicians have also combined bevacizumab with a second-line chemotherapeutic agent called gemcitabine.
Bevacizumab works to stop angiogenesis while other drugs have a direct toxic effect on cancer cells. Doctors worry that taking this medicine in combination with others may cause more side effects than usual.
Side Effects of Bevacizumab
Bevacizumab may cause dizziness, dry mouth, fatigue, heartburn and loss of appetite. In rare cases, it may cause severe side effects such as blood clots in the lungs, hemorrhaging, holes in the stomach and low white blood cell count. These potentially deadly complications are most common when it is used in conjunction with a chemotherapy drug.
A study of clinical trial results revealed that patients treated with bevacizumab and chemotherapy are 1.5 times more likely to die because of treatment complications than patients treated with chemotherapy alone.
Results of Bevacizumab Studies
A 2008 study tested the effects of bevacizumab with chemotherapy in 24 mesothelioma patients. They previously underwent other treatments with no positive results.
The combination was successful in slowing disease progression in half of patients. Overall, patients lived a median of 5.8 months after being treated with the drug. Researchers reported that it was well-tolerated and warranted further study.
In a case study the following year, a mesothelioma patient underwent treatment with bevacizumab and gemcitabine after other treatments had failed to shrink his tumor or control his symptoms. The combination helped prevent fluid buildup and pain, leading to a better quality of life.
This finding suggests that bevacizumab may aid in palliative, symptom-reducing care in addition to potentially curative, life-extending treatment.
This Page Contains 15 Cited Articles
The sources on all content featured in The Mesothelioma Center at Asbestos.com include medical and scientific studies, peer-reviewed studies and other research documents from reputable organizations.
- Raghav, K. et al. (2021, November). Efficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma. Retrieved from https://cancerdiscovery.aacrjournals.org/content/11/11/2738.abstract
- CancerHelp UK. (2011). How chemotherapy works. Retrieved from http://cancerhelp.cancerresearchuk.org/about-cancer/treatment/chemotherapy/about/how-chemotherapy-works
- Dowell, J.E. (2010). Cisplatin, Pemetrexed and Bevacizumab for Untreated Malignant Mesothelioma [Clinical Trial]. Retrieved from http://clinicaltrials.gov/ct2/show/NCT00295503
- Genentech. (2011). Product Information: Avastin. Retrieved from http://www.gene.com/gene/products/information/oncology/avastin/
- Jackman, D.M. et al (2008). Erlotinib Plus Bevacizumab in Previously Treated Patients with Malignant Pleural Mesothelioma. Cancer 113(4), 808-814. Retrieved from http://onlinelibrary.wiley.com/doi/10.1002/cncr.23617/pdf
- Janne, P.A. (2009). Bevacizumab (Avastin) and Erlotinib (Tarceva) in Previously Treated Mesothelioma [Clinical Trial]. Retrieved from http://clinicaltrials.gov/ct2/show/NCT00137826
- Kindler, H.L. (2010).Combination Chemotherapy with or without Bevacizumab in Treating Patients with Malignant Mesothelioma [Clinical Trial]. Retrieved from http://clinicaltrials.gov/ct2/show/NCT00027703
- Medline Plus. (2011). Bevacizumab Injection. Retrieved from http://www.nlm.nih.gov/medlineplus/druginfo/meds/a607001.html
- National Cancer Institute. (2011). Cancer Drug Information: Bevacizumab. Retrieved from http://www.cancer.gov/cancertopics/druginfo/bevacizumab
- National Cancer Institute. (2011). Cancer Drug Information: FDA Approval for Bevacizumab. Retrieved from http://www.cancer.gov/cancertopics/druginfo/fda-bevacizumab#Anchor-Dru-38018
- National Cancer Institute. (2006). Understanding Cancer Series: Angiogenesis. Retrieved from http://www.cancer.gov/cancertopics/understandingcancer/angiogenesis
- National Cancer Institute. (2011). When Combined with Chemotherapy, Bevacizumab is Associated with Increased Risk of Death. Retrieved from http://www.cancer.gov/clinicaltrials/results/summary/2011/bevacizumab-risk2011
- Rasul, K.I. & Kerr, D.J. (2009). Malignant peritoneal mesothelioma: is there a new treatment? Rare Tumors, 1(49), 150-152. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2994480/pdf/rt-2009-2-e49.pdf
- Robinet, G. &Scherpereel, A. (2011). Mesothelioma Avastin Plus Pemetrexed-cisplatin Study (MAPS) [Clinical Trial]. Retrieved from http://clinicaltrials.gov/ct2/show/NCT00651456
- Steenhuysen, J. (2011). Risk of death higher with Avastin than chemo alone.Reuters. Retrieved from http://www.reuters.com/article/2011/02/01/us-cancer-avastin-idUSTRE7108L720110201
Get Free Recipes for Mesothelioma Patients
Mesothelioma Trust Funds
Find Active Mesothelioma Clinical Trials
